Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Front Oncol · 2016 · PMC5086582 · PMID 27843803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

There was a weak trend observed in PK vs. body weight.

also in 834 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.